The company evaluated Comacadine in a clinical trial for 7mos. on patients (n=25) with diabetes mellitus who were on either insulin or metformin/glibenclamide treatment for 2 to 2.5yrs.
The results of the trial demonstrated 96% clinical remission in diabetes with no side effects, while 2 patients with high cholesterol experienced a decrease in their cholesterol levels when treated with Comacadine on which the company plans to initiate a clinical study
GrowLab will initiate an M&A transaction with NASDAQ listed SPAC or other multinational pharmaceutical companies for the commercial production of Comacadine to treat Diabetes, Glaucoma & Arthritis along with Grolatine to treat chronic pain, sickle cell disease & prostate cancer
Ref: PRNewswire | Image: GrowLab
